{
  "guideline": {
    "id": "PA166264881",
    "name": "Annotation of DPWG Guideline for phenytoin and HLA-B",
    "relatedChemicals": [
      {
        "id": "PA450947",
        "name": "phenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "source": "DPWG",
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451695800,
            "_label": "*15:02:01",
            "function": {
              "term": "Presence",
              "termId": "haplotypeTags:1445558333"
            }
          },
          {
            "id": 1451695784,
            "_label": "Other",
            "function": {
              "term": "Absence",
              "termId": "haplotypeTags:1445558334"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA532",
            "name": "chr6",
            "symbol": null
          },
          "strand": "minus",
          "id": "PA35056",
          "name": "major histocompatibility complex, class I, B",
          "symbol": "HLA-B"
        }
      }
    ],
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166264881",
    "version": 5
  },
  "annotationGroups": [
    {
      "id": "PA166264882",
      "name": "*15:02 negative",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Absence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782573,
        "html": "<p>The guideline does not provide a recommendation for phenytoin in patients with no HLA-B*15:02 alleles or negative for the.HLA-B*15:02 test.</p>\n"
      },
      "implications": {
        "id": 1451782572,
        "html": "<p>The guideline does not provide a description of the impact of the absence of HLA-B*15:02 alleles on phenytoin.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166264883",
      "name": "*15:02 positive",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Presence",
        "HLA-B:Presence/Presence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782575,
        "html": "<ul>\n<li>Carefully weigh the risk of SJS/TEN against the benefits</li>\n<li>Avoid phenytoin if an alternative is possible\n<ul>\n<li>Carbamazepine carries a 10-fold higher risk of SJS/TEN for these patients and is therefore not an alternative.</li>\n<li>A comparable risk has been reported for lamotrigine as for phenytoin. The same applies for oxcarbazepine, but the most severe forms (SJS/TEN overlap and TEN) are not observed with oxcarbazepine.</li>\n</ul>\n</li>\n<li>if it is not possible to avoid this medication, then advise the patient to report any skin rash immediately</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451782574,
        "html": "<p>The life-threatening cutaneous side effect Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) occurs more frequently in patients with this genetic variation. The calculated risk of phenytoin-induced SJS/TEN in patients with HLA-B*1502 is 0.65%.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": []
}